Figure 4: Metformin promotes AMPKα activation and autophagy induction in the kidneys with cisplatin-induced AKI. | Scientific Reports

Figure 4: Metformin promotes AMPKα activation and autophagy induction in the kidneys with cisplatin-induced AKI.

From: Metformin Protects Against Cisplatin-Induced Tubular Cell Apoptosis and Acute Kidney Injury via AMPKα-regulated Autophagy Induction

Figure 4

(A) Western blot assay showing the induction of LC3-II in the mouse kidneys after cisplatin injection. CD1 mice were injected with cisplatin (20 mg/kg) intraperitoneally, and the kidneys were collected at 1, 12 and 24 hours after injection. Numbers indicate the individual animal within each group. The gels were run under the same experimental conditions. (B) Western blot assay showing the abundance of p-AMPKα and LC3-II in cisplatin or cisplatin plus metformin treated kidneys. Numbers indicate the individual animal within each group. (C) The graph showing the results of semiquantitative analysis for p-AMPKα and LC3-II protein abundance among groups. *P < 0.05 compared to cisplatin treated cells (n = 3). The gels were run under the same experimental conditions. (D) Representative micrographs showing the immunofluorescent staining images for LC3β in kidneys. The intensive dot-like LC3β puncta were much more in the mice treated with metformin plus cisplatin comparing to those treated with cisplatin alone. Kidney sections were count stained with DAPI to visualize the nuclei. Bar = 20 μm.

Back to article page